Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program Read more about Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program
The Impact of the Inflation Reduction Act’s Drug Pricing Negotiation Program on Incentives for Clinical Development of New Drugs Read more about The Impact of the Inflation Reduction Act’s Drug Pricing Negotiation Program on Incentives for Clinical Development of New Drugs
How Time Is Accounted for When Modeling Pharmaceutical Impacts: Investment vs. Assessment Perspectives Read more about How Time Is Accounted for When Modeling Pharmaceutical Impacts: Investment vs. Assessment Perspectives
Analyzing Accelerated Approval for Oncology Drugs: NPC Commentary Evaluates Evidence on FDA Program Effectiveness, Concludes Benefits Outweigh Risks Read more about Analyzing Accelerated Approval for Oncology Drugs: NPC Commentary Evaluates Evidence on FDA Program Effectiveness, Concludes Benefits Outweigh Risks
Characterizing health plan evidence review practices: how often, how different, and how comprehensive? Read more about Characterizing health plan evidence review practices: how often, how different, and how comprehensive?
Making Informed Decisions: Assessing the Strengths and Weaknesses of Study Designs and Analytic Methods for Comparative Effectiveness Research Read more about Making Informed Decisions: Assessing the Strengths and Weaknesses of Study Designs and Analytic Methods for Comparative Effectiveness Research